Clinical observations on safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion.
OBJECTIVE
To observe the safety of fixed dose rate gemcitabine by intravenous infusion (iv-FDR) for cancers.


METHODS
From January 1, 2007 to December 31, 2009, four patients who were pathologically diagnosed with advanced pancreatic or breast cancer were recruited into this study. They were treated by gemcitabine 10mg/m2/min iv-FDR on days 1 and 8, and combined with other chemotherapeutics, repeated every four weeks. Toxicity was determined in line with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC).


RESULTS
The main toxicity was reversible myelosuppression; other side effects included gastrointestinal toxicity and liver impairment. Cardiac or renal toxicity was not detected.


CONCLUSIONS
The toxicity of iv-FDR gemcitabine combination chemotherapy was well tolerated, so that iv-FDR gemcitabine deserves to be further studied as a treatment option.
Yao
Cheng-Yun
CY
Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute, Nanjing, China.
Huang
Xin-En
XE
Tang
Jin-Hai
JH
Xu
Hong-Xia
HX
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D000093542:Gemcitabine
D003841:Deoxycytidine; D000093542:Gemcitabine